postoperative nausea and vomiting
Conditions
Interventions
Control Group:Sham auricular stimulation
Sponsors
Fifth Affiliated Hospital, Sun Yat-Sen University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Voluntarily signed informed consent; 2. Aged 18 to 75 years (inclusive), regardless of gender; 3. Patients scheduled for elective uniportal video-assisted thoracoscopic partial pulmonary resection under general anesthesia (including thoracoscopic wedge resection, thoracoscopic segmentectomy, and thoracoscopic lobectomy); 4. American Society of Anesthesiologists (ASA) physical status classification I–III; 5. Body mass index (BMI) between 18 and 30 kg/m²; 6. Apfel simplified risk score >=2 (based on four predictors: female gender, history of PONV and/or motion sickness, non-smoking status, and expected postoperative opioid use; each predictor is assigned 1 point, and the total score is calculated); 7. Postoperative use of intravenous patient-controlled analgesia (PCA) pump.
Exclusion criteria
Exclusion criteria: 1. History of vagus nerve injury, epilepsy, severe arrhythmia (e.g., sick sinus syndrome, second-degree or higher atrioventricular block, complete left bundle branch block), or bradycardia (resting heart rate < 50 bpm). 2. Known allergy or contraindication to any drug used in the study; 3. Skin lesions or damage at the stimulation site; 4. Preoperative use of medications that may affect the incidence of PONV (e.g., opioids, anticholinergics, or psychotropic drugs) that cannot be discontinued; 5. Presence of nausea or vomiting within 24 hours before surgery; 6. Severe hepatic, renal, cardiac, or pulmonary insufficiency (e.g., decompensated liver cirrhosis, renal failure requiring dialysis, NYHA class III–IV heart failure, pulmonary insufficiency requiring home oxygen therapy) or decompensated metabolic disease (e.g., diabetes mellitus with a history of ketoacidosis); 7. Psychiatric disorders, cognitive impairment, or any other condition that precludes cooperation with study assessments; 8. Concurrent participation in other clinical trials that may interfere with the results of this study; 9. Patients requiring postoperative admission to the intensive care unit (ICU).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence of postoperative nausea and vomiting within 48 hours after surgery; | — |
Secondary
| Measure | Time frame |
|---|---|
| Incidence of PONV in different time intervals;Severity of PONV;Incidence of PCIA discontinuation due to PONV;Number and dose of rescue antiemetic medication uses;Number and dose of rescue analgesic medication uses;NRS pain score;Cumulative opioid consumption of PCIA;Quality of Recovery-15 (QoR-15) score;Time to first ambulation after surgery;Time to first flatus or defecation after surgery;Time to first oral intake after surgery;Duration of chest tube drainage;Length of hospital stay;Patient satisfaction score for PONV management; | — |
Countries
China
Contacts
Public ContactYing Wang
Fifth Affiliated Hospital, Sun Yat-Sen University
Outcome results
None listed